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Abstract
Over the last few years, oncolytic virus therapy has been recognised as a promis-
ing approach in cancer treatment, due to the potential of these viruses to induce 
systemic anti-tumour immunity and selectively killing tumour cells. However, the 
effectiveness of these viruses depends significantly on their interactions with the 
host immune responses, both innate (e.g., macrophages, which accumulate in high 
numbers inside solid tumours) and adaptive (e.g., CD8+ T cells). In this article, we 
consider a mathematical approach to investigate the possible outcomes of the com-
plex interactions between two extreme types of macrophages (M1 and M2 cells), 
effector CD8+ T cells and an oncolytic Vesicular Stomatitis Virus (VSV), on the 
growth/elimination of B16F10 melanoma. We discuss, in terms of VSV, CD8+ and 
macrophages levels, two different types of immune responses which could ensure 
tumour control and eventual elimination. We show that both innate and adaptive 
anti-tumour immune responses, as well as the oncolytic virus, could be very impor-
tant in delaying tumour relapse and eventually eliminating the tumour. Overall this 
study supports the use mathematical modelling to increase our understanding of the 
complex immune interaction following oncolytic virotherapies. However, the com-
plexity of the model combined with a lack of sufficient data for model parametrisa-
tion has an impact on the possibility of making quantitative predictions.
Keywords Mathematical model · Oncolytic viruses · M1 macrophages · M2 
macrophages · CD8+ T cells
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1 Introduction
The increase in the incidence of skin cancers, combined with the advances in 
understanding the molecular biological mechanisms involved in tumour pro-
gression and interactions between melanoma cells and immune cells, has led to 
the development of several immune strategies for the treatment of these cancers 
(Dharmadhikari et  al. 2015). Among these strategies, the use of oncolytic viro-
therapies is emerging as an important approach in cancer treatment, due to their 
potential of inducing systemic anti-tumour immunity in addition to selectively 
killing cancer cells (Kaufman et al. 2016; Fukuhara et al. 2016; Filley and Dey 
2017). In spite of current expectations that oncolytic virus therapy will become in 
the future a standard therapy option for all cancer patients (Fukuhara et al. 2016), 
there are still limitations of this therapy. The reduced effectiveness of the onc-
olytic viruses injected into cancer patients depends not only on the pathogenic 
nature of virally encoded genes, but also on the interactions between the virus 
and the host innate and adaptive immune responses (Melcher et al. 2011; Kauf-
man et al. 2016; Fukuhara et al. 2016; Filley and Dey 2017).
Macrophages are one of the key innate immune cells involved in the regulation 
of anti-cancer immunotherapies, having either immuno-stimulatory or immuno-
suppresive effects (Allavena and Mantovani 2012). These cells can display dif-
ferent phenotypes, in response to the type, concentration and longevity of expo-
sure to stimulating agents (Cassetta et al. 2011). The two extreme macrophages 
phenotypes are represented by the M1 and M2 cells; see (Mantovani et al. 2002; 
Sica et  al. 2008; Allavena and Mantovani 2012) and also Fig.  1. Note that this 
M1-M2 classification follows the Th1–Th2 ( CD4+ T cells) classification, since 
the M1 cells are stimulated by Th1 cytokines, and M2 cells are stimulated by Th2 
cytokines (Allavena and Mantovani 2012). While it is accepted that the classi-
cally-activated M1 cells have anti-tumour properties and the alternatively-acti-
vated M2 cells have pro-tumour properties, many studies have shown that mac-
rophages inside the tumour microenvironment have markers characterising mixed 
phenotypes (Mantovani and Sica 2010; Allavena and Mantovani 2012; Italiani 
and Boraschi 2014). Because of the heterogeneity and plasticity of macrophages, 
it is very difficult to predict their impact on oncolytic virotherapies  (Jakeman 
et al. 2015; Denton et al. 2016). For example, it has been shown experimentally 
that the M2 macrophages can support these therapies through the suppression 
of the anti-viral immune response  (Denton et  al. 2016). The M1 macrophages 
may impede oncolytic therapies through the promotion of an anti-viral immune 
response that leads to viral clearance, but they also enhance the virus-mediated 
activation of the anti-tumour immune responses, which includes cells of the adap-
tive response such as CD8+ T cells (Denton et al. 2016).
In addition to the anti-viral innate immunity triggered by macrophages, as well 
as by other innate immune cells (e.g., neutrophils, natural killer (NK) cells; see 
Filley and Dey 2017), oncolytic therapies can be impeded also by various adaptive 
immune responses (e.g., CD8+ T cells; see Filley and Dey 2017; Melcher et  al. 
2011) and tumour/virus-induced cytokine production (e.g., IFN-훾 , TNF-훼 ; see 
1 3
Investigating Macrophages Plasticity Following Tumour–Immune…
Th1 cells
IL−12,
NO, ...
Classical
lipopolysaccharide (LPS)
IFNg
GM−CSF
IL−13
IL−10
IL−4
IL−10,
TGFb,
* Anti−inflammatory
(tissue repair)
* Immune suppression
Activation
stimuli:
activation
Alternative
* Induce Th1 responses
* Pro−tumour
* Induce Th2 responses
TGFb
VEGF, ...
Tumour progression
CD8 T cells(b)
M2 cells
M1 cells
(a)
activation
cells
Tumour
viruses
Oncolytic
promotion inhibition/death re−polarisation
M2 cells
Th2 cells
reciprocal promotion
immune
type−II
response
immune
response
M1 cellstype−I
* Immune activation
* Anti−tumour
* Pro−inflammatory
(tissue injury)
Characterised
by secretion
of:
Properties:
TNFa,
M2
M1
PAMPs/DAMPs
Fig. 1  a Classification of macrophages phenotypes, where cells are considered as part of a continuum, 
with the two extreme phenotypes of macrophages polarisation being represented by the classically 
activated M1 cells and the alternatively activated M2 cells. Tumour progression induces a M1→ M2 
polarisation (Mantovani and Sica 2010). Recent studies have also suggested a Th1 → Th2 polarisation 
during tumour progression [see, for example, Fig. 5 in Tatsumi et al. (2004)]. b Caricature description 
of the interactions between tumour cells, innate immunity (described here by M1 and M2 cells), adap-
tive immunity (described here mainly by the CD8+ T cells), and oncolytic viruses. Oncolytic viruses can 
lead to the production of viral pathogen-associated molecular patterns (PAMPs) that can be presented on 
the surface of tumour cells or released in the microenvironment (Pol et al. 2012), or danger-associated 
molecular patterns (DAMPs) that are released in the microenviromnent following virus-induced tumour 
lysis and which can promote macrophages activation (Martin 2016). In this figure we show also the Th1 
and Th2 CD4+ T cells, which interact with the M1 and M2 cells generating type-I and type-II immune 
responses (Allavena and Mantovani 2012; Mills 2012)
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Filley and Dey 2017), which can have direct anti-viral activities as well as immu-
noregulatory activities (Filley and Dey 2017). These complex immune–virus 
interactions lead also to the development of the two main approaches on onc-
olytic therapies: the virocentric point of view (which sees the immune system 
as an obstacle to viral replication), and the immunocentric point of view (which 
focuses on the immunogenicity of the viruses and their roles in inducing effec-
tor immune responses that can eliminate disseminated tumour cells) (Alemany 
and Cascallo 2009; Russell and Peng 2017). To overcome the current limitations 
of virotherapies, which in most of the cases are applied to immunocompromised 
patients  (Alemany and Cascallo 2009; Russell and Peng 2017), it is extremely 
important to investigate the complex interactions between oncolytic viruses and 
innate immunity (represented by pro-tumour/anti-tumour macrophages) as well as 
adaptive immunity (represented by CD8+ T cells).
In this study, we focus on a highly metastatic cell line, B16F10 melanoma, 
which is also resistant against the CD8+ cytotoxic T lymphocytes. Previous 
experimental studies with C57BL/6 mice have investigated the anti-tumour 
effects of CD8+ T cells following the inoculation of Vesicular Stomatitis Virus 
(VSV) particles, which take advantage of the impaired interferon pathways in 
tumour cells  (Hastie and Grdzelishvili 2012). In addition, experimental studies 
have shown that melanoma tumours can contain up to 30% macrophages (Hussein 
2006), and hence the elucidation of the interaction mechanisms between mac-
rophages and CD8+ T cells is very important in the context of oncolytic thera-
pies. Moreover, recent experimental results have emphasised the importance of 
macrophages on the motility and dissemination of murine melanoma cells (Roh-
Johnson et  al. 2017). However, to the best of our knowledge, not many exper-
imental studies have investigated in a quantitative manner (i.e., showing time-
series experimental data) the complex pro-tumour/anti-tumour effects of various 
innate and adaptive immune cells in the tumour microenvironment, following the 
administration of an oncolytic virus (e.g., VSV).
To address this, in our paper we aim to investigate at a theoretical level (i.e., 
using mathematical and computational approaches, combined with different pub-
lished experimental data), the interactions between the M1/M2 macrophages, the 
CD8
+ T cells primed by the macrophages (although they can also be primed by 
the dendritic cells Pozzi et al. 2005), and the VSV particles injected in a B16F10 
tumour. To keep the model relatively simple, we will ignore other innate immune 
cells in the tumour microenvironment, such as dendritic cells (DCs) (Pozzi et  al. 
2005), natural killer (NK) cells (Grundy et al. 2006), which have also been associ-
ated with increased tumour elimination (Grundy et  al. 2006). We will also ignore 
the explicit dynamics of CD4+ T helper cells, which have been shown to interact 
with the M1/M2 macrophages (Allavena and Mantovani 2012) and with the CD8+ 
T cells  (de Boer et al. 2003) during anti-tumour and anti-viral immune responses; 
see also Fig. 1b. However, we need to emphasise that due to the mirroring of the M1 
and Th1 immune responses, as well as the M2 and Th2 responses, even if we talk 
about M1 and M2 macrophages we think of [as suggested in Mills (2012)] the more 
broad type-I immune responses (i.e., responses generated by M1 and Th1 cells) and 
type-II immune responses (i.e., responses generated by M2 and Th2 cells).
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Mathematical and computational approaches have been widely used in the 
past to investigate the interactions between oncolytic viruses, tumour cells 
and immune cells (mainly cytotoxic T cells), with the overall aim of explain-
ing existing observations or generating new testable hypotheses; see (Nowak 
and May 2000; Wodarz 2001; Wodarz and Komarova 2009; Friedman et  al. 
2006; Bajzer et  al. 2008; Dingli et  al. 2009; Paiva et  al. 2009; Komarova and 
Wodarz 2010; Wu et  al. 2004; Eftimie et  al. 2011; Hofacre et  al. 2012; Rom-
melfanger et al. 2012; Crivelli et al. 2012; Macnamara and Eftimie 2015; Kim 
et al. 2015; Malinzi et al. 2015; Eftimie et al. 2016; Eftimie and Hamam 2017) 
and the references therein. The majority of these models focus on the tempo-
ral evolution of viral titers and immune cell responses, thus being described by 
ordinary differential equations. Fewer models focus also on the spatial distribu-
tion of viruses inside solid tumours (Paiva et al. 2009; Hofacre et al. 2012; Mal-
inzi et al. 2015; Timalsina et al. 2017; Malinzi et al. 2017). Other mathematical 
models have been derived to investigate the role of M1 and M2 macrophages 
(and other innate immune cells) on tumour dynamics, including B10F16 mela-
noma (Louzoun et al. 2014; den Breems and Eftimie 2016; Eftimie and Hamam 
2017; Phan and Tian 2017). A few other models investigated the anti-tumour 
effects of the interactions between innate and adaptive immune responses (Lou-
zoun et  al. 2014; Eftimie et  al. 2010), and even fewer models focused on the 
effects of innate and adaptive immunity on oncolytic viral therapies (Timalsina 
et al. 2017).
In the following, we use a mathematical approach to investigate the complex 
dynamics between the CD8+ T cells and M1 and M2 macrophages in the tumour 
microenvironment, with the overall aim of proposing new hypotheses regarding 
the mechanisms that could improve the anti-tumour effect of oncolytic viruses. 
In Sect. 2, we start with the experimental protocol introduced in Fernandez et al. 
(2002), where a Vesicular Stomatitis Virus (VSV) is injected into the system on 
two different days (days 10 and 13 after the inoculation of B16F10 melanoma 
cells), and use it to introduce a new mathematical model that quantifies the 
levels of virus infected/uninfected tumour cells, the levels of M1 and M2 mac-
rophages, the CD8+ T cells which have been previously shown to infiltrate B16 
murine melanoma, and the number of VSV particles. The model is parametrised 
using experimental data from Chen et  al. (2011), Fernandez et  al. (2002) (see 
also Fig. 2), and local sensitivity analysis is used to identify the parameters to 
which the tumour growth is most sensitive. We then use this model to investi-
gate the anti-tumour effects of the oncolytic VSV, and how these effects interact 
with the anti-tumour immunity generated by the CD8+ T cells and tumour-infil-
trating macrophages. In particular, we aim to answer three main questions: (I) 
Can this mathematical model be used to test various hypotheses proposed in the 
experimental literature to reduce tumour burden? (II) How does macrophages 
plasticity affect the oncolytic virotherapies? (III) How does the balance between 
innate and adaptive immune responses impact the evolution of the tumour? We 
conclude in Sect. 4 with a summary of the results and a discussion on data avail-
ability and model complexity.
 R. Eftimie, G. Eftimie 
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Fig. 2  a (i) Growth of B16F10 tumour cells and (ii) the re-polarisation of M1 and M2 mac-
rophages, as described by data re-drawn from Chen et  al. (2011). Here the authors injected mice 
with 5 × 106 tumour cells. For the numerical simulations we assume the following initial condi-
tions: xu(0) = 5 × 106 , xm1(0) = xm2(0) = 0 , xe(0) = 0 ; b Growth of B16F10 tumour cells in the 
presence of treatment with wild-type VSV, as described by data re-drawn from Fernandez et  al. 
(2002). Here, the authors injected mice with 5 × 105 tumour cells, and after palpable tumours were 
formed (of volumes ≈ 100mm3 ) the mice were treated twice (on days 10 and 13) with 2 × 107 
PFU of wild-type VSV. Mathematically, this VSV administration is described with the help of 
function H(t) = 2 × 107(Heaviside(t − 10) ⋅ Heaviside(11 − t) + Heaviside(t − 13) ⋅ Heaviside(14 − t)) . Since 
virus injection leads to tumour cell killing and release from the lysed cells of tumour-associated anti-
gens (TAAs), pathogen-associated molecular patterns (PAMPs) and danger-associated molecular pat-
terns (DAMPs), which can activate macrophages within hours (Martin 2016; Melzer et  al. 2017), and 
further lead to the activation of CD8+ T cells within 4–7 days (following the release of tumour-associated 
antigens Diaz et al. 2007b; Melzer et al. 2017), here we consider two values for the anti-tumour killing 
rates d
u
 and d
m1 , for before and after the detection of TAAs/PAMPs/DAMPs: dm1 = 0.01 for t < 11 and 
d
m1 = 0.29 for t > 11 , and du = 0.44 for t < 15 (i.e., 4–5 days after VSV leads to the release of DAMPs) 
and d
u
= 0.85 for t > 15 ; see sub-panel (b)(ii)
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2  Model Description
To investigate the effect of M1 and M2 macrophages on the anti-tumour oncolytic 
therapy with VSV and the interactions between macrophages and cytotoxic T cells, 
we consider a mathematical model that describes the time evolution of the following 
variables: the density of uninfected tumour cells ( xu ), the density of virus-infected 
tumour cells ( xi ), the density of virus particles ( xv ), the density of M1 macrophages 
( xm1 ), the density of M2 macrophages ( xm2 ) and the density of cytotoxic (effec-
tor) CD8+ T cells ( xe ); see also Fig.  1b. The time-evolution of these densities is 
described by the following equations: 
 These equations incorporate the following biological assumptions:
• The uninfected tumour cells, described by Eq. (1a), proliferate logistically with 
rate r, up to a carrying capacity K. Here, we assume a logistic growth because 
various experimental studies showed evidence of a reduced rate of tumour 
growth at larger sizes; see, for example, Laird (1964), Looney et  al. (1980), 
Guiot et al. (2003). Further, we assume that the virus particles infect, at a rate dv , 
only a certain proportion of the tumour (due to a multitude of obstacles associ-
(1a)
dxu
dt
= rxu
(
1 −
xu
K
)
− dvxv
xu
hv
u
+ xu
− duxu
xe
he + xe
− dm1xu
xm1
hm + xm2
+ dm2xu
xm2
hm + xm2
,
(1b)
dxi
dt
= dvxv
xu
hv
u
+ xu
− 훿ixi − d
v
u
xi
xe
he + xe
− dv
m1
xi
xm1
hm + xm2
,
(1c)
dxv
dt
=H(t) + 훿ibxi − 휔xv − d
v
u
xv
xe
he + xe
− dv
m1
xv
xm1
hm + xm2
,
(1d)
dxm1
dt
= av
1
(xi + xv) + a
u
1
xu + pm1xm1
(
1 −
xm1 + xm2
M
)
− xm1
(
r0
m1
+ru
m1
xu
hu + xu
)
+ xm2
(
r0
m2
+ rv
m2
xv
hv + xv
)
− dem1xm1,
(1e)
dxm2
dt
= au
2
xu + pm2xm2
(
1 −
xm1 + xm2
M
)
+ xm1
(
r0
m1
+ ru
m1
xu
hu + xu
)
− xm2
(
r0
m2
+ rv
m2
xv
hv + xv
)
− dem2xm2,
(1f)
dxe
dt
=pe
xm1
hm + xm2
− deexe − dtxuxe.
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ated with the tumour microenvironment   Wong et al. 2010). This can be mod-
elled using a saturated term for the tumour–virus interactions, with hv
u
 the half 
saturation constant for tumour cells infected with the oncolytic virus particles. 
The uninfected tumour cells can be eliminated at a rate du by IFN훾+ CD8+ T 
cells. Note that the saturated term in (1a) for tumour elimination by CD8+ T cells 
describes the fact that only a fraction of these cells are IFN훾 positive—see also 
(Bridle et al. 2010). Moreover, we assume that the uninfected tumour cells can 
be eliminated by the M1 cells at a rate dm1 , since high numbers of infiltrating M1 
macrophages are associated with good patient prognosis (Mantovani et al. 2006), 
and can eliminate mouse melanoma even in the absence of CD8+ T cells (Hara 
et al. 1995). The presence of M2 cells inhibits the anti-tumour immune response 
generated by these M1 cells (Sica et al. 2008). Finally, we assume that these M2 
cells support tumour growth at a rate dm2 , through the pro-tumour cytokines they 
secrete (Allavena and Mantovani 2012).
• The virus-infected tumour cells, described by Eq. (1b), die at a rate 훿i following 
viral replication and cell burst (see Eq. (1c)). The infected cells can be detected 
and eliminated at a rate dv
m1
(≫ dm1 ) by the M1 macrophages (Hashimoto et al. 
2007; Italiani and Boraschi 2014), or at a rate dv
u
(≫ du ) by the IFN훾+ CD8+ T 
cells (Bridle et  al. 2010). The anti-viral effect of M1 cells is inhibited by the 
presence of M2 cells.
• The virus, described by Eq. (1c), is injected into the system at some time t > 0 , 
and this virus administration is described by a function H(t) that is usually a 
combination of Heaviside functions; see caption of Fig. 2 for the description of 
H(t). The number of viral particles inside the tumour increases following the fast 
replication of these particles inside the tumour cells, causing the cells to burst 
open and release the particles. We denote by b the burst size, i.e., the number of 
viral particles released by one infected tumour cell. The half-life of these viral 
particles is 1∕휔 (with non-immune human and mouse serum neutralising VSV 
very quickly  Tesfay et al. 2013). Moreover, the M1 macrophages can promote 
an anti-viral immune response, which leads to early clearance of virus particles 
at a rate dv
m1
(Ciavarra et al. 2005; Denton et al. 2016). This viral clearance can be 
suppressed by the M2 macrophages (Denton et al. 2016). An anti-viral immune 
response is triggered also by the viral antigen-specific CD8+ T cells (Bridle et al. 
2010; Christensen et al. 2004), which can reduce the level of virus particles at a 
rate dv
u
 , e.g., through cytokine-mediated inhibition of viral replication (Komatsu 
et al. 1999; Christensen et al. 2004). We note that the rate at which the CD8+ T 
cells lyse the virus-infected cells could be different from the rate at which the 
virus particles are eliminated. For now we assume that both events are described 
by the same rate dv
u
 . However, in Sect. 3.1 we will discuss also the possibility of 
having different CD8+ T cells elimination rates for the virus-infected cells and 
for the virus particles.
• The M1 macrophages, described by Eq. (1d), are activated, at a rate av
m1
 , by 
viral pathogens and infected tumour cells that trigger the secretion of pro-
inflammatory cytokines (such as IFN-훾 ) (Labonte et al. 2014). This immune 
response could also be activated, at a small rate au
1
 , by the uninfected tumour 
cells—if the macrophages could detect these tumour cells. The recruitment 
1 3
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of M1 macrophages to the tumour site occurs at an average rate pm1 , up to a 
carrying capacity M (note that tissue-resident macrophages proliferate via a 
self-renewal process rather than through an influx of progenitors (Italiani and 
Boraschi 2014)). The M1→ M2 re-polarisation of macrophages occurs: (i) at a 
small constant rate r0
m1
 (due to cytokines, such as IL-4, IL-10, TGF-훽 , which 
can be produced by different types of healthy and immune cells), and (ii) at a 
tumour-dependent rate ru
m1
xu∕(hu + xu) (due to the anti-inflammatory cytokines 
produced by the tumour cells, e.g., TGB-훽 ). The re-polarisation of M2→ M1 
macrophages occurs at a small constant rate r0
m2
 (due to cytokines such as IFN-
훾 or IL-12 produced by different types of cells in the environment). Recent 
experimental studies have shown that oncolytic viruses can be genetically 
modified to carry chemokines and cytokines that can induce a M2→ M1 re-
polarisation (Guiducci et  al. 2005). We denote by rv
m2
 this virus-induced re-
polarisation rate, and for the beginning we consider rv
m2
= 0 ; the case rv
m2
> 0 
will be discussed in Sect. 3.3. Finally, the M1 macrophages have a death rate 
of dem1 (Yang et al. 2014; Italiani and Boraschi 2014).
• The M2 macrophages, described by Eq. (1e), are activated at a rate au
2
 by 
cytokines such as IL-4, IL-10, IL-13, TGF-훽 , which are usually associated 
with a tumour-promoting environment (Labonte et  al. 2014). These mac-
rophages proliferate logistically at an average rate pm2 , up to their carrying 
capacity M. The M2↔ M1 re-polarisation rates have been discussed in the 
previous paragraph. The M2 macrophages have a death rate of 1∕dem2 . Since 
many experimental studies on the turnover of macrophages do not distinguish 
between the M1 and M2 cells, throughout most of this study we will assume 
that pm1 = pm2 ∶= pm , and dem1 = dem2 ∶= dem . The cases where dem1 ≠ dem2 
and pm1 ≠ pm2 will be investigated in Sect.  3.1, in the context of sensitivity 
analysis.
• The cytotoxic CD8+ T cells, described by Eq. (1e), are activated and prolif-
erate at a rate pe in the presence of tumour and viral antigens presented by 
M1 macrophages (Pozzi et al. 2005; Olazabal et al. 2008). (We acknowledge 
that both dendritic cells (DCs) and macrophages can prime naive CD8+ T cells 
(Pozzi et  al. 2005), with the DCs being considered the most potent antigen-
presenting cells. However in this study we focus only on the macrophages 
since they are very abundant inside the tumour microenvironment, and thus 
they likely contribute to the initiation of T cell immunity. Moreover, the 
explicit inclusion of DCs in the model would only increase the complexity of 
the current system.) In contrast to other modelling studies on tumour–immune 
interactions following VSV therapy (see Macnamara and Eftimie 2015), here 
we assume that the tumour cells or virus particles do not influence directly 
the adaptive immune response, but they act through the innate response (M1 
cells) which then activate the T cells. This is biologically realistic as experi-
mental studies have shown that macrophage depletion suppressed the priming 
of CD8+ T cells (Ciavarra et al. 2000). Finally, the CD8+ T cells have a natural 
death rate de , and are inactivated by the tumour cells at a rate dt.
 R. Eftimie, G. Eftimie 
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Remark 1 Many mathematical models in the literature assume linear interactions 
between different components of the system; see, for example, (Dingli et al. 2009; 
Kim et al. 2015; Eftimie and Hamam 2017; den Breems and Eftimie 2016). While 
these assumptions simplify the analysis of the models, they might not always be 
realistic since many biological interactions occur in a saturated-like manner and thus 
can be phenomenologically described by saturated functions of the form x
c+x
 (where 
x is the variable under consideration, and c is a constant). As an example, experi-
mental data in Dudley et al. (2002) showed that the percentage lysis of tumour cells 
by cytotoxic immune cells is saturated (with very large numbers of immune effector 
cells not leading to more effective tumour killing). Neither the tumour–virus interac-
tions could always be described by linear interactions, since it would mean that 
larger numbers of oncolytic viruses would always kill the tumour. Experimental 
studies in Choi et al. (2018) with an oncolytic parapoxvirus showed that while virus 
levels of 103 , 104 and 105 PFU per tumour all lead to tumour reduction, the differ-
ences in tumour sizes were not always very significant— especially in later days 
(suggesting a sort of saturated effect). Regarding the VSV effects on B16F10 mela-
noma, the majority of studies in the literature focus on the percentage survival of 
mice. A different approach was shown in  Bridle et  al. (2009), where the authors 
investigated experimentally the effect of a fixed VSV level (i.e., 107 PFU of VSV) on 
different tumour sizes, and showed that mice survival was almost the same when 
1 × 106 or 2 × 106 B16F10 tumour cells were injected. Thus, in Eqs. (1a)–(1b) above 
we considered the term xv
xu
hv
u
+xu
 to account for this saturated effect in tumour size 
during tumour–virus interactions. This form for the virus infection term is consistent 
with other studies that model oncolytic virotherapies; see  (Wodarz and Komarova 
2009; Komarova and Wodarz 2010).
2.1  Parameter Approximation
To investigate the dynamics of tumour–immune–virus system (1), we first need 
to approximate the values of the parameters. In the following we discuss the 
approaches taken to identify the parameter values associated with tumour dynam-
ics alone, the parameter values for the tumour–immune interactions, and the param-
eter values associated with the virus dynamics. All these values are summarised in 
Table 1.
Nevertheless, before we discuss these approaches, we need to emphasise 
that in mathematical and computational immunology, many researchers have 
used parameters already published in the literature: either measured experimen-
tally following some particular experimental in  vivo and/or in  vitro studies, or 
parameters taken from other published mathematical and computational mod-
els (de Boer and Perelson 2013; Eftimie et al. 2016). This is a significant prob-
lem, since very few labs measure and estimate kinetics parameters, and even 
in this case the parameters are estimated for specific systems and might differ 
between studies (depending on the estimation method used, on the cell lines and 
virus strains used in the experiments, etc.) (de Boer and Perelson 2013; Eftimie 
et  al. 2016). The only rigorous approach of dealing with this problem—which 
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is both expensive and time consuming, but could lead to results that might have 
predictive power—is to estimate experimentally all parameters that appear in a 
model. In this study, we do not follow this rigorous approach, but rather follow 
the approaches taken by the majority of studies in the literature. To this end, we 
take some parameter values from the published immunological and mathematical 
literature (e.g., the in  vitro proliferation rates of B16F10 murine cells (Danciu 
et  al. 2013), the carrying capacity of macrophages (Eftimie and Hamam 2017), 
or the baseline M1↔ M2 re-polarisation rates (Wang et  al. 2012; Eftimie and 
Hamam 2017), while the rest of the parameters are approximated through model 
fitting to two different experiments with C57BL/6 mice (where we focus only on 
the control curves for tumour growth, and on the anti-tumour effect of wild-type 
VSV). Therefore, we do not expect that the results of this study will have pre-
dictive powers, but they will rather emphasise the range of various outcomes of 
tumour–virus–immune interactions.
• Tumour dynamics alone Experimental studies have shown that the murine 
B16 melanoma cells have a doubling time between 17.2 and 24 h (Danciu 
et  al. 2013; Calvet et  al. 2014). This corresponds to a proliferation rate of 
r ∈
(
ln(2)
(24∕24)
,
ln(2)
(17.2∕24)
)
= (0.69, 0.97)/day. For the simulations we use an average 
value of r = 0.924 corresponding to a doubling time of 18 h. Regarding the 
tumour carrying capacity K we focus on the data in Chen et al. (2011), where 
the maximum recorded tumour volume in the absence of any treatment was 
≈ 3000mm3 . Assuming that a volume of 1000mm3 contains approximately 109 
tumour cells (Friberg and Mattson 1997), we obtain a carrying capacity 
K = 3.0 × 109 cells.
• Immune response During steady state conditions, circulating monocytes have 
a half life of 1–3 days (Yang et al. 2014), with some class of murine mono-
cytes (Ly6C− ) exhibiting a longer steady-state half life of 5–7 days (Italiani 
and Boraschi 2014). Moreover, some macrophage populations can persist 
even longer, with the macrophages residing in intestinal lamina propria hav-
ing a half-life of 3 weeks, and the alveolar macrophages persisting for years 
(Yona et al. 2013). Throughout this study we consider an average cell death 
rate of dem = 0.2/day (corresponding to a half life of 3.4 days). In regard to the 
macrophages carrying capacity, we take the approach in Eftimie and Hamam 
(2017) and assume that M = 108 . We also assume that the anti-viral immune 
response is much stronger than the anti-tumour immune response, and thus we 
choose dv
u
= c0du , and dvm1 = c0dm1 , with c0 ≫ 1 . It is known that VSV is elimi-
nated from the blood within 2–4 days after inoculation (Johnson et al. 2009). 
Therefore, we choose c0 such that VSV particles persist in the system until 
day t = 17 (i.e., 3–4 days after their second inoculation), above a detection 
level of at least 100 PFU/ml (Hodges et al. 2012). This leads to c0 = 5.17 (so 
dv
m1
= 5.17 × dm1 and dvu = 5.17 × du for t > 10 when the VSV is introduced in 
the system). In regard to the CD8+ T cells, it is known that activated cells have 
a half-life of approximately 41 h (= 1.7 days), and a doubling time of about 8 
h (= 0.3 days) (de Boer et al. 2003). This cell turnover translates into a decay 
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rate dee = 0.4/day, and an activation/proliferation rate pe = 2.07 × 103cells/day 
(assuming that there is an order of 103 antigen-specific CD8+ T cells per 휇l of 
blood Bridle et al. 2009, 2010).
• Virus dynamics The burst size of the VSV varies between 50 plaque-forming 
units per cell (PFU/cell) to 8000 PFU/cell, with an average of 2500 PFU/cell 
(Zhu et al. 2009). Here we consider a baseline parameter value for the burst 
size of b = 2500 . Moreover, VSV-infected cells are lysed by the virus particles 
within 30–40 h post infection (Zhu et al. 2009). Assuming an average of 35 h, 
we thus consider 훿i = ln(2.0)∕35h=0.47/day. Regarding the intracellular half-
life of VSV particles, it has been shown in DePolo and Holland (1986) that 
it can vary between 5.3 and 12.5 h, depending on the viral mutant. Moreover, 
the extracellular half-life of retroviral vectors pseudotyped with VSV-G gly-
coprotein is between 3.5 and 8 h (Hwang and Schaffer 2013). In this study we 
assume a VSV half-life of 8 h, which corresponds to a baseline viral death rate 
휔 = ln(2.0)∕(8∕24)/day=2.0/day.
To approximate the rest of the parameters associated with the anti-tumour immune 
response, we fit the model to two different B16F10 data sets from C57BL/6 mice, 
where we consider only the control data for tumour-growth curves (i.e., no addi-
tional treatments to boost up the anti-tumour or anti-viral immune responses). For 
the oncolytic virus, we focus only on the wild-type VSV (and its impact on the 
B16F10 cells).
• We first fit model (1) with no VSV ( xv(t) = xi(t) = 0 ) to the mean of (control) 
tumour data in Chen et al. (2011) (see Fig. 2a), since the injection of 5 × 106 
tumour cells into immunocompetent C57BL/6 mice likely triggers both innate 
and adaptive immune responses. Moreover a tumour doubling time of 18 h for 
B16F10 cells, as recorded in Danciu et al. (2013), Calvet et al. (2014), cannot 
explain the slow tumour growth in Chen et al. (2011)—see also Fig. 2a. The 
baseline tumour and immune parameter values ( du , hu , hm , he , dm1 , dm2 , au1 , 
au
2
 , pm , r0m1 , r0m2 , rum1 ) obtained from this fitting are listed in Table 1. We must 
emphasise that given the very large parameter space, the values identified rep-
resent only one possible set of parameters that can fit the data. We also note 
that to be able to explain the M1:M2 ratios on days 7 and 14 (see Chen et al. 
2011) we need to have au
1
≫ au
2
 . Moreover, the M1→ M2 re-polarisation rate as 
a result of tumour growth ( ru
m1
 ) needs to be much larger than the baseline re-
polarisation rates ( r0
m1
 and r0
m2
).
• Finally, we fit the full model (1) (with VSV) to the mean of B16F10 tumour 
growth data in Fernandez et al. (2002), where the mice received 2 × 107 PFU 
of the wild-type VSV. The virus-related parameter values ( av
1
 , dv , hvu ) that gen-
erated these baseline results are listed in Table  1. Note that these identified 
parameter values depend on our assumption that the CD8+ T cells and M1 
macrophages eliminate at the same rates the infected/uninfected tumour cells 
and the VSV particles. Since we had five free parameters ( av
1
 , dv , hvu , dve , dvm1 ) 
that we could vary to fit the model (1) to the data, to obtain the best fit shown 
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in Fig. 2 we had to incorporate also the assumption that the VSV injection (on 
day t = 10 ) induces the release of tumour-associated antigens (TAAs), path-
ogen-associated molecular patterns (PAMPs) and danger-associated molecu-
lar patterns (DAMPs), which can activate macrophages within hours (Martin 
2016; Melzer et al. 2017), and further lead to the activation of CD8+ T cells 
within 4–7 days (following the release of tumour-associated antigens Diaz 
et  al. 2007b; Melzer et  al. 2017). Thus, we chose: dm1 = 0.01 for t < 11 and 
dm1 = 0.29 for t > 11 , and du = 0.44 for t < 15 , and du = 0.85 for t > 15 ). How-
ever, in the next section we will also discuss the situation when we assume 
that there are no different immune responses before/after VSV injection.
Finally, we note that the initial conditions for the in silico simulations performed 
throughout this study are summarised in Table 2.
3  Results
In the following we start the investigation into the role of macrophages on onco-
lytic virotherapies by performing first a local sensitivity analysis, to identify those 
parameters to which the model is most sensitive and to see which of these param-
eters are important in macrophages polarisation. Then we focus on a few virus-
related and immune-related parameters (some identified as important during the 
sensitivity analysis), which will be varied to reproduce different experimental and 
clinical approaches aimed at controlling tumour growth. In this context, we will 
discuss the effect of varying these parameters on the size of M1 and M2 popula-
tions, and how this correlates with tumour control/elimination. This investigation 
will address mainly question (I) from the Introduction. To address questions (II) 
and (III) we will combine numerical simulations for transient system dynamics 
with steady-state analysis of long-term dynamics.
Table 2  Summary of initial conditions used for the numerical simulations of system (1) throughout 
Sect. 3. These initial conditions aim to replicate the experimental conditions in Fernandez et al. (2002)
Variable Description Initial conditions
xu Density of uninfected tumour cells (cell numbers per volume) the day when 
the oncolytic virus is introduced
xu(0) = 5 × 10
5
xi Density of virus-infected tumour cells (cell numbers per volume) xi(0) = 0
xv Density of virus particles (described as particles forming units (PFU) per 
volume)
xv(0) = 0
xm1 Density of M1 macrophages (cell numbers per 휇l of blood) xm1(0) = 0
xm2 Density of M2 macrophages (cell numbers per 휇l of blood) xm2(0) = 0
xe Density of CD8+ T cells (cell numbers per 휇l of blood) xe(0) = 0
 R. Eftimie, G. Eftimie 
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3.1  Sensitivity Analysis
Before investigating the transient and long-term dynamics of model (1), we perform 
a local sensitivity analysis to obtain a first understanding on the importance of anti-
tumour viral responses (i.e., virocentric perspective) versus anti-tumour immune 
responses (i.e., immunocentric perspective). Since we are interested in identify-
ing the parameters that can slow down tumour relapse, we investigate the relative 
changes in tumour size on day t = 20 [an arbitrarily-chosen day, when the tumour is 
growing back following the second VSV injection; see Fig. 2b(i)]. We compute this 
relative change as follows (Hamby 1994; Olufsen and Ottesen 2013):
where paramnew = paramold ± 80%paramold . We chose to vary the baseline param-
eters by ± 80% as we aim to explore large parameter fluctuations around these base-
line values, which are also proportional to the magnitudes of the parameters identi-
fied in Table 1.
Δxu
xu
/||||Δparamparam |||| = x
old
u
(20) − xnew
u
(20)
xold
u
(20
/|||||param
old − paramnew
paramold
|||||,
21
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Fig. 3  Relative sensitivity of tumour size on day t = 20 to ± 80% changes in the baseline parameter val-
ues listed in Table 1. We denoted by dt<11
m1
 and dt<15
u
 the values of d
m1 and du before the M1 and CD8+ T 
cells response to the release of TAAs/PAMPs/DAMPs by the virus-lysed tumour cells. Also, we denoted 
by dt>11
m1
 and dt>15
u
 the values of d
m1 and du after the increase in the M1 and CD8+ T cells response to the 
release of TAAs/PAMPs/DAMPs. For rv
m2
 we started with an arbitrary value of rv
m2
= 0.5 (much smaller 
than the baseline value of ru
m1
 ), which we then varied by ±80%
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Figure  3 shows that tumour relapse (on day t = 20 ) is most sensitive to the 
virus-induced M2→ M1 re-polarisation ( rv
m2
 ), as well as to the anti-tumour CD8+ 
T cell immune response ( dt<15
u
,dt>15
u
 ), the anti-tumour M1 immune responses fol-
lowing the lysis of tumour cells by the VSV particles and the release of TAAs/
PAMPs/DAMPs ( d>11
m1
 ), the half-saturation density of M2 cells that inhibit the 
anti-tumour M1 responses ( hm ), the pro-tumour M2 responses ( dm2 ), and the 
tumour-induced M1↔ M2 re-polarisation rate ( ru
m1
 ) combined with the half-satu-
ration density of tumour cells that trigger the M1↔ M2 re-polarisation ( hu ). Other 
parameters that can impact significantly tumour relapse are: the tumour prolif-
eration rate (r), the tumour carrying capacity (K), the activation rate of M1 cells 
( au
1
 ), the proliferation rate of M2 cells ( pm2).
Note that with the exception of rv
m2
 , which will be discussed in more detail in 
Sect.  3.3, the model does not seem to be particularly sensitive to the majority 
of virus-related parameters, even when some of these parameters are quite large; 
e.g., see b, 훿i in Table 1. This suggests that the virus alone might not have much 
impact on tumour control/elimination. Rather these outcomes are the results of 
the combined effect between viruses and anti-tumour immune responses, repre-
sented here by the CD8+ T cells and M1 cells. Moreover, the fact that the tumour-
induced macrophages re-polarisation rate ru
m1
 has such a big impact on tumour 
decay suggests that any oncolytic virotherapies should take into consideration 
also the effect of tumour environment on macrophages polarisation.
Overall, these sensitivity results emphasise the importance of both innate and 
adaptive immunity on tumour relapse, thus supporting the immunocentric point 
of view (Alemany and Cascallo 2009). Another aspect emphasised by these sensi-
tivity results is that even small changes in these immune-related parameters (due 
to environmental heterogeneity and stochasticity Satija and Shalek 2014; Jimé-
nez-Sánchez et al. 2017; Papalexi and Satija 2018) could affect significantly the 
outcome of the oncolytic viral therapy and the survival of the patient.
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Remark 2 We have also investigated (not shown here) tumour sensitivity to the rate 
at which the CD8+ T cells lyse the virus particles, which we separated from the rate 
at which the CD8+ T cells lyse the virus-infected cells. The sensitivity results did not 
show any significant difference compared to the case when these two rates are the 
same (see tumour sensitivity to dv
u
 , in the bottom panel of Fig. 3).
In the following we use model (1) to investigate different immunological hypothe-
ses associated with changes in the parameters to which the tumour is most sensitive.
3.2  Baseline Model Dynamics
We start the investigation into the dynamics of model (1) by showing in Fig. 4(a) 
the baseline dynamics when the VSV is injected on days t = 10 and t = 13 [as in 
Fernandez et  al. (2002)]. In this case, the presence of the oncolytic virus that is 
detected for up to 4 days after the last injection (assuming that detection threshold 
is 102PFU/ml Hodges et  al. 2012), leads to a slow-down in tumour growth. This 
slow-down in tumour growth is also the result of a large CD8+ T cell population 
(Fig. 4(c)) and a large M1:M2 ratio (Fig. 4(b)). Tumour relapse is associated with 
both a small M1:M2 ratio and a large M1+M2 population, as well as a small CD8+ 
T cell population.
Next, we move away from the experimental studies in Fernandez et  al. (2002), 
Chen et  al. (2011) and investigate whether model (1) can reproduce various anti-
tumour treatment approaches proposed by different experimental studies. The 
parameters that we will vary in this context, which can be controlled experimentally, 
will help us further propose hypotheses regarding the best approaches for tumour 
control/elimination.
3.3  Changes in Virus‑Related and Immune‑Related Parameters
Changes in virus-induced macrophages re-polarisation rate rv
m2
 . Since the sensitiv-
ity analysis showed that one of the parameters that have the largest impact on tumour 
dynamics is rv
m2
 , next we investigate the assumption that the oncolytic virus is engi-
neered to induce a M2→ M1 re-polarisation (Guiducci et al. 2005; Masemann et al. 
2018). We need to emphasise that such a M2→ M1 macrophage re-polarisation has 
been obtained experimentally with oncolytic adenoviruses (Guiducci et al. 2005) or 
oncolytic influenza viruses (Masemann et al. 2018). A very recent study (McCan-
less 2019) also showed that a VSV strain can induce a M2→ M1 re-polarisation in 
the context of breast cancer, as determined by the increased secretion of TNF-훼 —a 
cytokine associated with M1 responses, and also with CD8+ T cell responses (Ber-
trand et al. 2016). To investigate computationally the effect of increasing the virus-
induced M2→ M1 re-polarisation rate in the context of B16F10 melanoma, next we 
assume that rv
m2
= 0.5 . Figure 5 shows the dynamics of model (1) when we consider 
multiple VSV treatments: (a) two VSV treatments (as in Fernandez et al. (2002)), 
(b) three VSV treatments. First, we note that tumour reduction and eventual elimina-
tion is always associated with a large percentage of M1 macrophages (while tumour 
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relapse is associated with an increased percentage of M2 macrophages). Second, we 
note that a third round of VSV injection could lead to a persistent CD8+ T cells 
response (panel (b)(iii)), which eventually causes tumour elimination; this response 
is consistent with previous experimental observations on the activation of CD8+ 
cells following VSV delivery  (Bridle et  al. 2009). Note that in this case, the total 
number of tumour-infiltrating macrophages does not seem to play a major role in 
tumour elimination or persistence—only the ratio M1:M2 does. Therefore, we can 
speculate that offering multiple rounds of oncolytic therapies with viruses aimed 
at re-polarising the macrophages towards a M1 phenotype (e.g., GM-CSF-armed 
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Fig. 5  Dynamics of model (1) when we assume that the oncolytic virus can induce a M2→ M1 re-
polarisation: rv
m2
= 0.5 . a We consider two VSV injections of 2 × 107PFU on days t = 10 and t = 13 ; b 
We consider three VSV injections of 2 × 107PFU on days t = 10 , t = 13 and t = 16 . Sub-panels (i) show 
the tumour-immune-virus dynamics, sub-panels (ii) show the percentages of M1 and M2 cells on days 
t = 12 , t = 15 , t = 20 and t = 30 , and sub-panels (iii) show the total number of M1+M2 macrophages 
and total numbers of CD8+ T cells on days t = 12 , t = 15 , t = 20 , t = 30
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viruses; Deng et al. 2016), which leads to an increase in the rv
m2
 rate, could improve 
current oncolytic and immune cancer therapies.
Changes in virus-related parameters Next, we investigate the dynamics of model 
(1) as we vary the main virus-related parameter ( dv ) to which the tumour is not very 
sensitive (see Fig.  3), but which is important in the context of anti-tumour treat-
ments as many experimental studies emphasise the importance of improving the 
delivery of these viruses into the tumour cells (Vähä-Koskela and Hinkkanen 2014). 
Figure 6(a) shows that a significant increase (i.e., by a factor of 4) in the rate dv at 
which the oncolytic virus infects the tumour cells can lead to tumour control (for 
t ∈ (15, 25) ) and even tumour elimination (for t > 27 ). This tumour clearance is 
 dv=0.044      r    =2.0
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the result of a very large viral infection (see the curves for xv and xi in panel (a)
(i)), which is then followed by a large immune response. Note that the immune 
response following tumour clearance is characterised by a very large number of 
macrophages (M1+ M2), with a large M1:M2 ratio. It can be easily checked that 
similar virus-induced tumour elimination can be obtained if we decrease (e.g., by 
a factor of 4) the killing rates of virus particles by the CD8+ T cells ( dv
e
 ) and M1 
cells ( dv
m1
 ), to simulate a reduction in the anti-viral immune response as suggested 
by many experimental and clinical studies; e.g., via immunosupressive chemothera-
peutics such as cyclophosphamide, which affects both CD8+ T cell and macrophage 
populations (Filley and Dey 2017; Santosuosso et al. 2002; Hanoteau et al. 2017). 
Therefore, we can speculate that by increasing the rate at which the oncolytic virus 
infects the tumour cells (e.g., by focusing on the reduction of physical barriers 
inside the tumour, which allows for better virus spread (Alzahrani et al. 2019; Vähä-
Koskela and Hinkkanen 2014), or by focusing on the reduction of anti-viral immune 
responses), we could also trigger large sub-sequent anti-tumour innate and adaptive 
immune responses that might lead to permanent tumour elimination.
Changes in tumour-induced macrophages re-polarisation rate ru
m1
 . Over the past 
few years, various experimental and clinical studies focused on preventing the dif-
ferentiation of M2 macrophages for better anti-tumour outcomes (e.g., by depriving 
the tumour of growth factors and thus preventing the M1→ M2 differentiation; see the 
review in Heusinkveld and van der Burg (2011) or the clinical study in Coward et al. 
(2011)). To investigate this treatment approach, next we study computationally the 
effect of decreasing parameter ru
m1
 which controls this tumour-induced M1→ M2 differ-
entiation. Figure 6b shows that a significant decrease in the re-polarisation rate ru
m1
 can 
lead to tumour control (and even elimination; e.g. for ru
m1
= 1 , not shown here). Here, 
tumour control is the result of a relatively large CD8+ T cell population, which seems 
to dominate the immune response for t ∈ (15, 25) , and a very large M1:M2 ratio 
(although the macrophages population as a whole, M1+M2, is quite low). The VSV 
level is relatively low, as the anti-tumour and anti-viral immune responses control the 
dynamics of the system. These numerical results are consistent with some experimen-
tal studies showing the activation of CD8+ T cells following the administration of 
VSV (Bridle et al. 2009). However, the tumour relapse triggered by the increase in the 
total number of macrophages (as well as the M2:M1 ratio), suggests the necessity of 
tracking experimentally not only the T cells’ response to VSV [as done in Bridle et al. 
(2009)], but also the interactions between T cells and macrophages.
Overall, Figs. 5 and 6 suggest that there are two mechanisms through which the 
tumour is kept under control and even eliminated: a viral-dominated response (as 
in Fig. 6a) and an immune-dominated response (as in Fig.  5b). We need to empha-
sise that the viral-dominated anti-tumour response generates quickly a very strong 
immune response that ensures persistent tumour elimination. This kind of dynamics 
might lead to a confusion as to whether the tumour is eliminated by the immune 
response or by the viral replication. We stress that these two mechanisms (virocen-
tric vs. immunocentric) depend on the model parameters, which can be different for 
different cells inside the same patient (as shown by a recent clinical study on the 
heterogeneity of tumour–immune microenvironments; see Jiménez-Sánchez et  al. 
2017).
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Changes in anti-tumour immunity rates Finally, we investigate the effect of 
shifting the immune response from viral antigens to tumour antigens, for exam-
ple, by injecting oncolytic viruses that carry TAAs (Bridle et al. 2010; Melcher 
et  al. 2011). In our model, this is described by the increase the tumour killing 
rates of CD8+ T cells ( du ) and M1 cells ( dm1 ) before/after the release of TAAs/
PAMPs/DAMPs from the lysed tumour cells. Figure  7 shows three types of 
immune responses that can lead to tumour control/elimination: (a) an immune 
response characterised by relatively low M1:M2 ratios, a very large number 
of tumour-infiltrating macrophages (M1+M2), and a relatively small number 
( < 3500 at t = 30 ) of CD8+ T cells; (b) an immune response characterised by high 
M1:M2 ratios, a small number of tumour-infiltrating macrophages (M1+M2), and 
a high number ( > 5800 at t = 30 ) of CD8+ T cells; (c) an immune response char-
acterised by relatively high M1:M2 ratios, a small number of tumour-infiltrating 
macrophages (M1+M2), and a median number ( ≈ 5500 at t = 30 ) of CD8+ T 
cells. The most puzzling outcome is the one shown in panels (a), since one would 
expect to see tumour relapse when M2>M1. We suspect that the relatively simi-
lar numbers of M1 and M2 cells (the M2 population is only slightly larger than 
the M1 population), together with the very large dt>15
u
 value describing a very 
(c) d    =0.01, d    =0.6m1t<11 m1
(iii)
(ii)
Pe
rc
en
ta
ge
 M
1 
an
d 
M
2 
ce
lls
Pe
rc
en
ta
ge
 M
1 
an
d 
M
2 
ce
lls
t>15 t>11
Pe
rc
en
ta
ge
 M
1 
an
d 
M
2 
ce
lls
%M1 cells
%M2 cells
%M1 cells
%M2 cells
%M1 cells
%M2 cells
(iii)
u(a) d  =0.44, d  =1.35t<15
(i)
(ii)
(b) d  =0.58, d  =0.85uuu t<15 t>15
(iii)
(ii)
(i)
M1+M2 cells
CD8 T cells
M1+M2 cells
CD8 T cells
M1+M2 cells
CD8 T cells
V
SV
 p
ar
tic
le
s/
vo
l
N
um
be
rs
 o
f c
el
ls
/v
ol
,
V
SV
 p
ar
tic
le
s/
vo
l
N
um
be
rs
 o
f c
el
ls
/v
ol
,
V
SV
 p
ar
tic
le
s/
vo
l
N
um
be
rs
 o
f c
el
ls
/v
ol
,
(i)
N
um
be
rs
 o
f i
m
m
un
e 
ce
lls
N
um
be
rs
 o
f i
m
m
un
e 
ce
lls
t=20 t=30t=15t=12 t=12 t=15 t=20 t=30t=12 t=30t=20t=15
VSV detection
Tum. detection
VSV detection
Tum. detection
VSV detection
Tum. detection
t=15 t=20 t=30t=12 t=12 t=15 t=20 t=30t=12 t=15 t=20 t=30
N
um
be
rs
 o
f i
m
m
un
e 
ce
lls
Fig. 7  Dynamics of model (1) as we increase the following parameters: a dt>15
u
= 1.35 ; b dt<15
u
= 0.58 ; 
c dt>11
m1
= 0.6 . All other parameters are as in Table  1. Sub-panels (i) show the whole dynamics of the 
system; sub-panels (ii) show the percentages of M1 and M2 cells on days t = 12 , t = 15 , t = 20 , t = 30 ; 
sub-panels (iii) show the total size of the macrophage (M1+M2) and CD8+ T cell populations on days 
t = 12 , t = 15 , t = 20 , t = 30
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strong anti-tumour CD8+ T cell response despite low CD8+ T cell numbers, play 
an important role in controlling tumour growth/elimination. This result is consist-
ent with the outcome of various experimental approaches focused on priming of 
CD8
+ T cells with oncolytic viruses that carry TAAs (Diaz et al. 2007a; Bridle 
et al. 2009, 2010), which showed enhanced anti-tumoural activities via increased 
IFN-훾 production and not via increased T cell numbers (Diaz et al. 2007a). How-
ever, this increased anti-tumoural activity is still difficult to control in cancer 
patients, and is the subject of continuous research.
We note here that varying other immune parameters to which the tumour is 
sensitive—see Fig.  3—leads to a model dynamics similar to the one shown in 
Fig.  7. Moreover, we believe that using other sets of parameters that could fit 
the data in Chen et  al. (2011) and Fernandez et  al. (2002) would likely lead to 
tumour-immune-virus dynamics similar to the cases shown in Figs. 5, 6 and 7.
3.4  Long‑term Dynamics: Steady States and Their Stability
The numerical simulations presented in the previous sections suggested the 
possibility of having long-term behaviours characterised by tumour elimina-
tion and the persistence of an immune response, or behaviours characterised by 
the coexistence of tumour and immune cells. In the following we aim to obtain 
a better understanding of these behaviours by focusing on the steady states 
(x∗
u
, x∗
i
, x∗
v
, x∗
m1
, x∗
m2
, x∗
e
) exhibited by model (1). To this end, we focus only on the 
following three cases: (i) tumour-absent states (that can shed slight on the com-
binations of parameters that can lead to tumour elimination); (ii) tumour-pre-
sent virus-absent states (that can shed light on the combinations of parameters 
important in anti-tumour immunity); and (iii) tumour-present, virus-present and 
immune-present states (that can shed light on the combinations of parameters 
important in anti-tumour and anti-viral immunity, as well as oncolytic activities).
 (i) Tumour-absent states Since the previous numerical results (e.g., Fig. 6b) 
showed that tumour could be eliminated, in the following we investigate the 
conditions on various parameters that ensure the existence of tumour-free 
steady states and their stability. To this end, we focus on the steady states that 
have xu = 0 . Using Eqs. (1b)–(1c) this implies that xi = 0 and xv = 0 . The 
steady-state values for the immune cells are given by (see also Appendix A): 
  where
(2a)
x∗
m1
=
x∗
m
r0
m2
r0
m1
+ r0
m2
, x∗
m2
=
x∗
m
r0
m1
r0
m1
+ r0
m2
, x∗
e
=
pe
dee
x∗
m
r0
m2
(r0
m1
+ r0
m2
)hm + x
∗
m
r0
m1
,
(2b)
x∗
m
=
(pm − dem)M
pm
> 0, and
pm ∶= pm1 = pm2, dem ∶= dem1 = dem2.
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 Here, x∗
m
= x∗
m1
+ x∗
m2
 , the total macrophage population at steady state. It is 
possible to have also x∗
m1
= x∗
m2
= x∗
e
= 0 , but this state is always unstable 
and we will not investigate it any further. Note that these immune-present 
tumour-free states (2) depend on the baseline re-polarisation rates r0
m2
 and 
r0
m1
 , as well as on the proliferation and death rates of macrophages and CD8+ 
T cells. In Fig.  8a(i)–(ii) we graph these states in the ( r0
m1
, r0
m2
)-space—
mainly to see. We observe that the tumour-free state can be characterised by 
x∗
m1
> x∗
m2
 (for r0
m2
> r0
m1
 ) or by x∗
m1
< x∗
m2
 (for r0
m1
> r0
m2
 ). The tumour-free 
steady state (0, 0, 0, x∗
m1
, x∗
m2
, x∗
e
) , with x∗
m1
 , x∗
m2
 and xe given by Eq. (2) is 
asymptotically stable provided that the parameters listed in Table 1 satisfy 
the following inequality: 
 The proof is given in Appendix A. The surface described by the left-hand-
side of inequality (3) is sketched in Fig. 8b. More precisely, in Fig. 8b(i) we 
sketch the expression that appears in the left-hand-side of the inequality (3) 
(3)r − du
x∗
e
he + x
∗
e
− dm1
x∗
m1
hm + x
∗
m2
+ dm2
x∗
m2
hm + x
∗
m2
< 0.
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Fig. 8  a Tumour-free steady state ( 0, 0, 0, x∗
m1
, x∗
m2
, x∗
e
 ); Sub-panels (i)–(ii) show the immune states (ver-
sus r0
m1
 and r0
m2
 ) as given by equations (2) (where the very low x∗
e
 value is the result of h
m
= 1000 — see 
Eq. (2a)); the red curve in sub-panel (iii) describes the intersection of the surfaces defining the three 
immune states in the ( x∗
m1
, x∗
m2
, x∗
e
 ) space; here we fix r0
m1
= r0
m2
= 0.001 , as in Table 1. b Stability regions 
for the tumour-free steady state, in the parameter space given by ( r0
m1
, r0
m2
, d
u
 ), as we vary the anti-
tumour/pro-tumour immune responses. The surface describes the left-hand-side of (3), when it becomes 
equal to zero, and thus separates the stability and instability regions. (i) baseline d
m1 and dm2 values (as in 
Table 1); (ii) d
m1 = 0.6 , dm2 = 0.4 ; (iii) dm1 = 0.2 , dm2 = 0.1 . All other parameter values are as in Table 1
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for the baseline parameter values shown in Table 1, while in Fig. 8b(ii),(iii) 
we sketch it for different dm1 and dm2 values. Note that the stability region 
increases over the ( r0
m1
, r0
m2
)-space for large du and dm1 , as well as for small 
dm2.
 (ii) Tumour-present virus-absent states Since the previous numerical simulations 
(see Figs. 4, 5, 6 and 7) showed that the virus is always eliminated (which is 
consistent with experimental studies discussing VSV neutralisation by non-
immune human and mouse serum; see Tesfay et al. 2013), next we focus on 
the steady states ( x∗
u
, 0, 0, x∗
m1
, x∗
m2
, x∗
e
 ). These states are given implicitly by 
the following two equations, which were obtained by combining the steady-
state Equations (1a) and (1f) (where, for simplicity, we assumed in (1a) that 
dm2 × x
∗
m2
∕(hm + x
∗
m2
) ≈ dm2 × c with c ∈ (0, 1) ), and by adding the steady-state 
Equations (1d) + (1e), where pm = pm1 = pm2 and dem = dem1 = dem2 : 
 Here x∗
m
= x∗
m1
+ x∗
m2
 . Note that (4b) holds true only if the last two 
terms on the right-hand-side are negative, which is equivalent to 
x∗
m
> (pm − dem)M∕pm . Thus, when tumour is present the total macrophages 
state is higher than the state x∗
m
 obtained for the tumour-free case [see (2b)]. 
In Fig. 9 we investigate the steady state as we vary (a) the scaling parameter 
c ∈ (0, 1) , (b) the rate du at which the CD8+ T cells eliminate the tumours, 
and (c) the rate dm1 at which the M1 cells eliminate the tumour. Note that 
an increase in c does not change the value of x∗
m
 but it leads to an increase 
in x∗
u
 (due to a larger M2 cell population). Moreover, while the change in du 
(4a)0 ≈r
(
1 −
x∗
u
K
)
− du
x∗
e
he + x
∗
e
− dm1
(
dee
pe
x∗
e
+
dt
pe
x∗
u
x∗
e
)
+ dm2c,
(4b)0 =(au1 + au2)x∗u + pmx∗m
(
1 −
x∗
m
M
)
− demx
∗
m
.
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Fig. 9  Steady states ( x∗
u
, 0, 0, x∗
m1
, x∗
m2
, x∗
e
 ) as given by the intersection of the surfaces (4a) and (4b), 
for three different values of: a the approximating parameter c: c = 0.2 , c = 0.6 and c = 0.85 ; b we fix 
c = 0.2 and vary the elimination rate d
u
 of tumour by CD8+ T cells, from d
u
= 0.34 → d
u
= 0.54 ; c we 
fix c = 0.2 and vary the elimination rate d
m1 of tumour by M1 cells, from dm1 = 0.22 → dm1 = 0.82 . Note 
that here we graph the total macrophage population x∗
m
= x∗
m1
+ x∗
m2
 , and the variations in c, d
u
 and d
m1 do 
not seem to affect significantly this total x∗
m
 population, only the x∗
u
 population.
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affects significantly the long-term tumour size, the change in dm1 does not 
seem to have a significant impact on tumour size when x∗
e
 is small. However, 
larger x∗
e
 values can lead to tumour reduction as we increase dm1 , and thus we 
deduce that it is the combined effect of (anti-tumour) macrophages and CD8+ 
T cells that controls tumour growth. As it will be discussed in Appendix A, 
the complexity of model (1) makes it very difficult to investigate analytically 
the stability of these steady states, to determine their long-term persistence 
(although numerical simulations suggest that the state is stable for the param-
eter values in Table 1; see also Fig. 10b). We would like to emphasise that 
the existence of this tumour-present virus-absent state is connected to the 
instability of the previous tumour-free steady state, since this tumour-present 
state is given by 
 which is strictly positive when the inequality (3) is violated. In Fig. 10a we 
show the regions in the ( r, dm2 ) parameter space where the tumour-present 
virus-absent state exists or not-depending on the sign of equation (5). In 
Fig. 10b we fix r = 0.374 and vary dm2 within (0.02, 0.2), to be at the border 
of the stability region for the tumour-free state. We can see that the tumour-
free state is stable for dm2 ≤ 0.075 and unstable for dm2 > 0.075 . When 
dm2 = 0.068 , a second branch of unstable non-zero tumour-present virus-
absent states arises; this is shown in Fig. 10(b) on the logarithmic scale. These 
states stabilise around dm2 = 0.159 . We note that for dm2 ∈ (0.068, 0.091) and 
(5)x∗u =
K
r
(
r − du
x∗
e
he + x
∗
e
− dm1
x∗
m1
hm + x
∗
m2
+ dm2
x∗
m2
hm + x
∗
m2
)
,
d
d
uu
lo
g(
x*
) 
stable
unstable
tumour−yes
virus−no
state
saddle−
focus
state
tumour−yes
stable
virus−no
state
(and r=0.374 fixed)
x* does not existx* exists
m2
m2
sa
dd
le
sa
dd
le
(a)
r
(b)
x*
 =
0
u
(w
he
n 
x*
>
0)
u
tumour−free
unstable
tumour−free
state
u
Fig. 10  a Diagram in the ( r, d
m2)-space showing the existence of the tumour-present virus-absent state 
( x∗
u
, 0, 0, x∗
m1
, x∗
m2
, x∗
e
 ), as given by Eq. (5). b Bifurcation diagram showing the existence and stability of 
the tumour-free state ( 0, 0, 0, x∗
m1
, x∗
m2
, x∗
e
 ) and the tumour-present virus-absent state ( x∗
u
, 0, 0, x∗
m1
, x∗
m2
, x∗
e
 ), 
as we vary the parameter d
m2 in Equation (5) over the range (0.03, 0.2) while fixing r = 0.374 ; this 
parameter range is indicated also in a, where we see a transition between existence and non-existence of 
the tumour-present virus-absent x∗
u
 state.
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dm2 ∈ (0.146, 1.158) all eigenvalues of the Jacobian matrix (see Appendix A) 
are real (corresponding to saddle points), while for dm2 ∈ [0.092, 0.145] two 
eigenvalues of the Jacobian matrix are complex (corresponding to saddle-
focus points). This suggests that another bifurcation occurs for dm2 ≈ 0.092 
and dm2 ≈ 0.145 , which might lead to oscillations. (We decided not to inves-
tigate these possible oscillations here since they occur for r = 0.374≪ 0.924 
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Fig. 11  Steady state ( x∗
u
, x∗
i
, x∗
v
, x∗
m1
, x∗
m2
, x∗
e
 ) as given by Eqs. (6)–(6), when we vary: a parameter 
c = x∗
m2
∕(h
m
+ x∗
m2
) ∈ (0.1) which gives some information about the density of M2 cells (and implic-
itly the density of M1 cells, as x∗
m1
= x∗
m
− x∗
m2
 . We focus on two cases: (i) b = 1 , and (ii) b > 1 (with 
C0 = 6 × 10
6 in (6)); b the rate dv
m1
 at which the M1 cells eliminate the virus and virus-infected cells; c 
the rate dv
u
 at which the CD8+ T cells eliminate the virus and virus-infected cells; d the rate d
v
 at which 
the virus infects the tumour cells. The rest of parameters are as in Table 1
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the proliferation rate of B16F10 cells.) Moreover, since both states with no 
virus are unstable for dm2 ∈ (0.068, 0.159) it is likely that the dynamics of the 
system will approach a steady state where all tumour cells, immune cells and 
virus particles are present (see below).
 (iii) Tumour-present virus-present immune-present states To investigate the relation 
between anti-tumour and anti-viral immune responses, as well as the oncolytic 
activities of VSV particles, next we focus on the tumour-present virus-present 
and immune-present (quasi-) steady states ( x∗
u
, x∗
i
, x∗
v
, x∗
m1
, x∗
m2
, x∗
e
 ). (Recall that 
numerical simulations have shown that the virus is usually eliminated a few 
days after it is injected, and thus the presence of the virus characterises a 
quasi steady state.) In Fig. 11a–d we graph, for different parameter values, the 
surface given by the following equation, 
which connects the cell population states x∗
u
 , x∗
e
 , and x∗
m
= x∗
m1
+ x∗
m2
 . To investigate 
how these steady states, and in particular x∗
u
 depends on the density of virus parti-
cles (or the density of infected cells), we use a second equation defined in terms of 
x∗
vi
∶= x∗
v
∕x∗
i
 and x∗
u
 , which is graphed in Fig. 11e:
 For details on how these equations were obtained, see Appendix A.
Regarding the changes in viral and immune parameters, we notice in Fig. 11 that:
• For the parameter values in Table 1, the tumour-present states exit only for rela-
tively low ratios x∗
vi
= x∗
v
∕x∗
i
< 800 ; see panel (e). Moreover, the rate dv at which 
the oncolytic virus infects the tumour cells does not have a significant impact on 
the persistence of very large tumours (i.e., tumours with x∗
u
> 108 ); variations in 
dv are effective for medium-sized tumours and they impact the ratio x∗vi.
• Changes in the value of c = x∗
m2
∕(hm + x
∗
m2
) , which gives an indication on the 
level of M2 macrophages in the system, does not seem to have a significant effect 
on x∗
u
 ; see panel (a). Also note that for the parameter values investigated here, 
when x∗
e
∈ (1.2 × 104, 1.5 × 104) and x∗
m
< 105 ), there are two possible tumour 
states x∗
u
 : one below x∗
u
≈ 107 , and one above this threshold. This result is par-
ticularly interesting since Friberg and Mattson (Friberg and Mattson 1997) sug-
(6)
1
av
1
(
−x∗
u
(au
1
+ au
2
) − x∗
m
(pm − dem −
pm
M
x∗
m
)
)
⋅(
dv
u
x∗
e
he + x
∗
e
− dv
m1
x∗
e
pe
(du − dtx
∗
u
)
)
− rx∗
u
(
1 −
x∗
u
K
)
+ dux
∗
u
x∗
e
he + x
∗
e
+ dm1x
∗
u
x∗
e
pe
(dee − dtx
∗
u
) + dm2x
∗
u
c = C0, with C0 =
{
0, b = 1,
> 0, b > 1.
(7)dvx∗vi
x∗
u
hv
u
+ x∗
u
− 훿i + 휔 −
훿ib
x∗
vi
= 0.
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gested that the tumours are detected when their size is above 107 cells. Thus, for 
relatively similar immune responses ( x∗
m
 and x∗
e
 ) and fixed parameter values, one 
could obtained large tumours (i.e., x∗
u
> 109 cells) or tumours below the detection 
threshold. Finally, by comparing the steady-state surfaces generated in sub-panel 
(a)(ii) for b = 1 and b > 1 , we conclude that a higher viral burst size ( b > 1 ) is 
associated with a larger CD8+ T cell population, as well as a smaller tumour size 
and a smaller macrophage population x∗
m
.
• As expected from the sensitivity analysis, the rate dv
m1
 at which the M1 cells 
eliminate the virus particles and the virus-infected tumour cells does not have 
a significant impact on the very large tumour steady states; see panel (b). How-
ever, changes in dv
m1
 affect the medium-size tumours, by reducing the range in x∗
e
 
over which there is possible to have two tumour sizes (above/below the detection 
threshold). Also, an increase in dv
m1
 leads to a slight decrease in x∗
e
 . This unex-
pected behaviour is probably the result of the indirect effect of M1 macrophages.
• The rate dv
u
 at which the CD8+ T cells eliminate the virus particles and virus-
infected tumour cells also has an impact on the small-to-medium size steady 
states, with lower dv
u
 being associated with lower x∗
e
 states; see panel (c).
• For the parameter values in Table  1, the changes in the rate du at which the 
CD8
+ T cells eliminate the uninfected tumour cells do not seem to have a signifi-
cant effect on small and very large tumours. The only observable effect is on the 
existence of two different tumour sizes (below and above the detectable threshold 
of 107 ), which occur also for smaller x∗
e
.
Since it is impossible to obtain closed-form solutions for the tumour-present steady 
states (due to the high dimensionality of the system (1), and the presence of satu-
rated terms), it is very difficult to investigate analytically the stability of these steady 
states in terms of various model parameters (see also Appendix A). This is one of 
the issues associated with complex mathematical models that aim to investigate 
complex interactions between multiple components of the biological systems.
4  Summary and Discussion
In this study we introduced a mathematical model for the investigation of the inter-
actions between melanoma tumour cells, an oncolytic Vesicular Stomatitis Virus 
(VSV) that was administered twice in 3 days, and innate and adaptive immune 
responses. We first parametrised the model without the oncolytic virus by fit-
ting it to baseline experimental data in Chen et  al. (2011), which focused on the 
anti-tumour/pro-tumour immune response of the M1 and M2 macrophages. Then, 
we fixed the tumour and immune-related parameters, and fit the full model with 
the oncolytic virus (VSV) to the baseline experimental data in Fernandez et  al. 
(2002). To ensure a better model-to-data fit, we incorporated the assumption of 
higher anti-tumour immune responses following the first viral infection, which 
leads to the release of TAAs, PAMPs and DAMPs by destroyed tumour cells. For 
the parameters shown in Table 1, the anti-tumour immune responses following the 
VSV injection ( dt>15
u
= 0.85 , dt>11
m1
= 0.29 ) are much greater than the anti-tumour 
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immune responses before VSV injection ( dt<15
u
= 0.44 , dt<11
m1
= 0.01 ). However, 
since the value of the anti-tumour immune response following VSV injection ( dt>15
u
 , 
dt>11
m1
 ) depends on the multitude of fixed tumour and immune parameters (identified 
through fitting the data in Chen et al. (2011)), and since it is likely that one can find 
multiple sets of tumour and immune parameters that can fit the data in Chen et al. 
(2011), we expect that it is possible to find also lower immune responses that fit the 
data in Fernandez et al. (2002). However, this sort of parameter investigation was 
not the aim of this current study. Rather, our goal was to investigate whether we can 
use only one class of mathematical models to reproduce and explain the dynamics 
suggested by data generated by two different experimental systems, and to further 
investigate the overall model dynamics. A global parameter optimisation, which can 
be used to fit at the same time multiple different experiments, will be the subject of a 
different study. We should emphasise here that despite the possibility of having dif-
ferent sets of parameter values that fit the same data, we would not expect significant 
changes in the overall dynamics of the system (1) - see also Figs. 5, 6, 7.
Using the model derived in this study we then investigated the different tumour-
immune-virus dynamics exhibited by model (1). Thus, through simulations we 
identified two types of anti-tumour responses, a viral-dominated response and an 
immune-dominated response (see Fig. 6), which can coexist in the same system and 
are dependent on different model parameters. Note that the increased viral oncolysis, 
which leads to tumour elimination in Fig. 6, seems to be immediately followed by 
an increased anti-tumour immune response that ensures persistent tumour elimina-
tion. Despite the numerically identified virus-induced tumour elimination observed 
in Fig. 6a(i) for large dv values, sensitivity analysis (Fig. 3) showed that variations 
in dv within ±80% of the identified baseline value could not trigger tumour elimina-
tion. It is possible that the baseline value of the virus-infection rate dv = 0.011 is 
too low for sufficient virus replication inside tumours. Therefore, unless the tumour-
immune-virus microenvironment is perturbed in such a way that allows for higher 
virus spread, the tumour might never be eliminated. Examples of experimental 
approaches that have been used to increase viral spread include the use of immu-
nosuppresive chemotherapeutic agents such as cyclophosphamide (Filley and Dey 
2017), to reduce the rates at which the immune cells eliminate the virus. Mathemati-
cally, this means a reduction in dv
u
 and dv
m1
 baseline values (see Table 1). Numerical 
simulations, not shown here since they are similar to those shown in Fig. 6a, confirm 
that a reduction by a factor of 4 of these two rates (i.e., to dv
u
= 1.1 and dv
m1
= 0.375 ) 
leads to tumour elimination due to increased viral replication—thus supporting the 
importance of viral oncolysis. Moreover, as in Fig. 6, this tumour clearance phenom-
enon is followed almost immediately by an increase in CD8+ T cells and M1 cells 
levels, thus ensuring that tumour elimination persists for long periods of time. In 
regard to the anti-tumour immunity following the injection of oncolytic viruses, we 
have seen in Fig. 5b that multiple VSV injections could eliminate a tumour that is 
otherwise kept under control by the immune system. One should be aware that larger 
doses of VSV could have neurotoxic effects (Bridle et  al. 2009). Therefore, while 
multiple VSV injections could lead to better anti-tumour outcomes, one needs to 
investigate also the optimal level of VSV that is therapeutically safe for the patients.
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In the context of question (II) from the Introduction, we showed in Fig. 11 that 
the macrophages’ plasticity (as quantified by c) did not seem to have a big impact 
on small and large tumours, but might have some impact on medium-size tumours, 
i.e., tumours around the detection threshold ( x∗
u
≈ 107 ). In the context of question 
(III) we noted that the complex interactions between innate and adaptive immuno-
therapies might lead to intriguing results, where an increase in the anti-viral innate 
response (described by dv
m1
 ) has led to a decrease in the number of CD8+T cells that 
was further associated with a slight increase in the possible tumour sizes. Finally, 
anti-tumour oncolytic virotherapy (as controlled by dv ) seemed to have an effect 
only on medium-to-large tumours.
Simplicity vs. complexity in mathematical immunology The complexity of the 
immune response, and in particular the tumour–immune interactions in the context 
of macrophages plasticity with multiple cell phenotypes, could lead us to think that 
incorporating more details into the mathematical models might shed light on the 
specific aspects of the immune responses that could control tumour growth. For 
example, one could think that understanding the detailed interactions between the 
adaptive and innate immunity, or the different aspects of innate immunity, or the sat-
urated vs. linear interactions between tumour cells, immune cells and/or virus par-
ticles, might help us find the mechanisms that could control tumour growth. While 
these specific details could indeed help us investigate (mostly numerically) their 
role on the overall dynamics of the model, the complexity of the new models that 
contain large numbers of equations/terms makes them very difficult to be investi-
gated analytically (see Appendix), to draw general conclusions about the importance 
of specific sets of parameters on tumour control. Moreover, the new models have 
very large parameter spaces (even after non-dimensionalisation—not shown for this 
study). Sensitivity analysis could be used to identify the parameters that are most 
likely to influence model dynamics, but the results are dependent on the baseline 
parameter values/ranges (obtained through model parametrisation or just guessed).
As shown in Fig. 1, we could have included in system (1) also a Th1–Th2 adap-
tive immune response (which mirrors the M1-M2 macrophages response), but the 
model would have been even more complex, and even less informative. Or we could 
have incorporated other immune cells, such as the NK cells that support oncolytic 
virotherapies (Diaz et al. 2007a; Bhat and Rommelaere 2015).
In the context of visualising the behaviour of our tumour-immune-virus system, 
we need to emphasise that the large number of equations in model (1), which under-
lines the complexity of this model, can lead to some difficulties regarding the calcu-
lation of the steady states and their visualisation. In Figs. 8, 9 we graph in 3D two of 
the simpler steady states exhibited by model (1), as we vary some model parameters. 
While the 3D-plots are not always very helpful, they might be necessary for a basic 
understanding of the behaviour of complex models—as shown in Sect. 3.4.
We conclude this discussion by emphasising that such complex mathematical 
models can only be used to qualitatively investigate the possible dynamics of the 
system. Moreover, we emphasise that one should strive for simplicity in modelling, 
as long as the model incorporates all the predominant elements/variables required to 
answer specific biological questions, and as long as the model can be fitted to avail-
able data.
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Model parametrisation In the published literature, there is very little immunological 
data that can be used to parametrise mathematical models. The majority of published 
experimental papers show time series of tumour growth, with extremely few papers 
showing time series of various immune responses. Moreover, when both such time 
series can be found, those for the tumour growth are not always obtained under the 
same conditions (i.e., the same mouse line, the same treatment, etc.), as the time series 
for the immune responses. To parametrise (relatively complex) mathematical models 
for tumour–immune interactions, one option is to use multiple data sets obtained in dif-
ferent experimental settings and to further investigate model sensitivity to the identified 
parameters. In this study we used two different data sets from Fernandez et al. (2002), 
Chen et al. (2011) where, for consistency, we focused exclusively on the baseline con-
trol tumour data (i.e., B16F10 melanoma data obtained in the absence of any external 
treatment) and macrophages immune data in C57BL/6 mice. However, we should have 
also parametrised the model using VSV decay data and CD8+ T cells data—but we 
could not find such data. Note that this type of model parametrisation using multiple 
data sets is somehow similar to the use of parameters taken from various published 
studies (a very common practice in mathematical immunology, but which leads to 
more variation in parameter values).
Therefore, for a mathematical model to provide quantitative results that could be 
used to make predictions which could further inform experiments, it is necessary to 
parametrise it using sufficient data. Thus more close collaborations between mathemat-
ical modellers and experimentalists are necessary to move this field forward.
5  Appendix A: Linear Stability of Steady States
The linear stability of the steady states (xu, xi, xv, xm1, xm2, xe) is given by the eigenval-
ues of the Jacobian matrix (J) associated with system (1):
and ai,j the terms obtained after differentiating the right-hand-sides of Eq. (1) with 
respect to the model variables.
At the steady state (0, 0, 0, x∗
m1
, x∗
m2
, x∗
e
) , we obtain a12 = a13 = a14 = a15 = a16 = 0 , 
a21 = a23 = a24 = a25 = a26 = 0 , a31 = a34 = a35 = a36 = 0 . By writing down the 
non-zero terms in this Jacobian matrix one can easily observe that det(J − 휆핀6) = 0 
(with 핀6 the 6 × 6 identity matrix) has the following eigenvalues:
(8)J =
⎛⎜⎜⎜⎜⎜⎜⎝
a11 a12 a13 a14 a15 a16
a21 a22 a23 a24 a25 a26
0 a32 a33 a34 a35 a36
a41 a42 a43 a44 a45 0
a51 0 a53 a54 a55 0
a61 0 0 a14 a15 a16
⎞⎟⎟⎟⎟⎟⎟⎠
, with aij ≥ 0,
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From here is it easily observed that asymptotic stability would require 𝜆1 < 0 (see 
Equation (3)). The other two eigenvalues ( 휆4,5 ) are given by the roots of a quadratic:
where
and
We note that B > 0 since pm(1 −
x∗
m
M
) − dem = 0 (from the definition of x∗m ; see Eq. 
(2b)). Since A < 0 and B > 0 we deduce that 𝜆4,5 < 0 . Therefore, the stability of the 
tumour-free state is given exclusively by the sign of 휆1 , as requested by Equation (3).
Remark 3 Note that to calculate the tumour-free virus-free steady state 
(0, 0, 0, x∗
m1
, x∗
m2
, x∗
e
) given by Equations (2), we used the steady-state Equation (1f) 
to obtain x∗
e
 , and the steady-state Equations (1d) and (1e) (in which we substituted 
the expression for x∗
m
= x∗
m1
+ x∗
m2
 , with x∗
m
 satisfying (2b)) to obtain x∗
m1
 and x∗
m2
 . 
For example,
𝜆1 =r − du
x∗
e
he + x
∗
e
− dm1
x∗
m1
hm + x
∗
m2
+ dm2
x∗
m2
hm + x
∗
m2
,
𝜆2 = − 𝛿i − d
v
u
x∗
e
he + x
∗
e
− dv
m
x∗
m1
hm + x
∗
m2
< 0,
𝜆3 = − 𝜔 − d
v
u
x∗
e
he + x
∗
e
− dv
m1
x∗
m1
hm + x
∗
m2
< 0,
𝜆6 = − dee < 0.
휆4,5 =
1
2
�
A ±
√
A2 − 4B
�
,
A = −pm + dem − (r
0
m1
+ r0
m2
) < 0 since pm > dem (for x
∗
m
to exist),
B =
[
pm
(
1 −
x∗
m
M
)
− dem
]2
−
[
pm
(
1 −
x∗
m
M
)
− dem
][
pm
x∗
m
M
+ r0
m1
+ r0
m2
]
+
pmx
∗
m
M
(r0
m1
+ r0
m2
).
(1d) ⇒ 0 = x∗
m1
(
pm
(
1 −
x∗
m
M
)
− dem
)
− x∗
m1
r0
m1
+ (x∗
m
− x∗
m1
)r0
m2
⇔ 0 = x∗
m1
(
0
)
⏟ ⏟
Eq.(2b)
−x∗
m1
r0
m1
+ (x∗
m
− x∗
m1
)r0
m2
⇒ x∗
m1
=
x∗
m
r0
m2
r0
m1
+ r0
m2
.
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In a similar manner one can use the steady state Equation (1e) to obtain the expres-
sion for x∗
m2
.
At the steady state (x∗
u
, 0, 0, x∗
m1
, x∗
m2
, x∗
e
) , given implicitly by Eq. (4), we obtain 
a12 = 0 , a21 = a24 = a25 = a26 = 0 , a31 = a34 = a35 = a36 = 0 . The eigenvalues 
휆 of the Jacobian matrix satisfy a 6th-order polynomial, which cannot be solved 
explicitly (to identify the combinations of parameters that control the stability of the 
steady states). Moreover, as we can see in Fig. 9, for fixed parameter values there 
seem to be an infinite number of possible steady states.
The coefficient terms in this 6th-order polynomial are even more compli-
cated if we consider the tumour-present virus-present immune-present states 
(xu, xi, xv, xm1, xm2, xe) . Therefore, the complexity of the model (and in particular 
the presence of nonlinear saturated terms) renders almost impossible the classical 
linear stability analysis (although stability can be calculated numerically for spe-
cific parameter values, as shown in Fig. 10).
Remark 4 Not only that we cannot investigate the stability of the tumour-present 
virus-present immune-present steady stats, but even finding closed-form equations 
for these states is challenging. To obtain the implicit Eqs. (6)–(7) that describe these 
states, we started with Equation (1f) from which we obtained
Then, adding (1b)+(1c) in which we substitute the above expression leads to
For b = 1 the first term on the right-hand-side vanishes. If b > 1 , we can denote this 
first term by C0.
If we now focus on the steady-state Eq. (1a), and solve for the same term 
dvx
∗
v
x∗
u
∕(hv
u
+ x∗
u
) while denoting by c = x∗
m2
∕(hm + x
∗
m2
) ∈ (0, 1) , we obtain :
Equating (9) and (10) leads to the following equation (which combines (1a), (1b), 
(1c) and (1f)):
x∗
m1
hm + x
∗
m2
=
x∗
e
pe
(
dee − dtx
∗
u
)
(9)dvx∗v
x∗
u
hv
u
+ x∗
u
= −훿ix
∗
i
(b − 1) − (x∗
i
+ x∗
v
)
(
dv
u
x∗
e
he + x
∗
e
− dv
m1
x∗
e
pe
(dee − dtx
∗
u
)
)
.
(10)
dvx
∗
v
x∗
u
hv
u
+ x∗
u
= rx∗
u
(
1 −
x∗
u
K
)
− dux
∗
u
x∗
e
he + x
∗
e
− dm1x
∗
u
x∗
e
pe
(dee − dtx
∗
u
) + dm2x
∗
u
c.
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On the other hand, combining the steady-state Eqs. (1d) and (1e) leads to
Substituting (12) into (11) leads to Equation (6).
To obtain (7), we eliminate the similar terms in (1b) and (1c) that contain x∗
e
 and 
x∗
m1
 , namely dv
u
x∗
e
∕(he + x
∗
e
) + dv
m1
x∗
m1
∕(hm + x
∗
m2
) . This leads to
Denoting by x∗
vi
∶= x∗
v
∕x∗
i
 , the above equation reduces to (7).
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